TB 500 Interactions: Alcohol, Caffeine, Food and Other Compounds

Questions about combining a research peptide with everyday substances — a drink, a coffee, a meal, another peptide — arrive far faster than the studies needed to answer them. For TB-500, a synthetic peptide related to the actin-binding protein thymosin beta-4, the gap is wide. The published record contains preclinical injury-model work and narrative reviews of peptides in regenerative and gerontological contexts, but it does not contain controlled interaction experiments pairing TB-500 with ethanol, caffeine, or a defined fed or fasted state. This page describes that record as it stands, labels mechanistic reasoning as reasoning rather than evidence, and does not evaluate whether any combination is advisable.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision, medication or substance. Nothing here describes a protocol, and no combination is endorsed or discouraged.

What the verified literature on TB-500 actually contains

The most directly relevant primary work is an animal study in which researchers examined BPC-157 and TB-500 in a rat Achilles tendon healing model using histopathological and biomechanical endpoints (PMID 42542926). That design is an injury-repair experiment, not an interaction experiment: the study's comparators were peptide-treated and control tendon groups, not peptide-plus-alcohol or peptide-plus-caffeine groups (PMID 42542926).

Surrounding that primary work are two review-level sources. A comprehensive review of peptides in regenerative medicine surveyed clinical applications in tissue repair and chronic pain management and discussed where the evidence base remains preliminary (PMID 42635865). A separate review of therapeutic peptides in gerontology described mechanisms and applications relevant to healthy aging (PMID 42021992). Neither review is an interaction review, and neither reports head-to-head testing of a peptide against a dietary or recreational substance (PMID 42635865).

Because no dose of TB-500 can be stated here that the verified sources support, no dosing figures appear anywhere on this page. Where a number would ordinarily go, the honest description is that the experimental parameters sit inside the cited papers and were not reproduced from any secondary source.

TB-500 and alcohol

Direct evidence: none identified. No study in the verified set administered ethanol alongside TB-500 or measured any pharmacokinetic, pharmacodynamic or tissue-level outcome of that pairing. The rat tendon study did not include an alcohol arm (PMID 42542926), and the regenerative-medicine review did not describe ethanol co-exposure among the clinical applications it surveyed (PMID 42635865).

Mechanistic reasoning, not evidence: researchers who discuss this question generally reason from two separate literatures rather than from a combined one. First, peptides of this class are typically administered parenterally and are subject to peptidase degradation rather than extensive hepatic first-pass metabolism, which is the pathway most commonly invoked when alcohol alters drug handling. Second, alcohol is independently discussed in tissue-repair contexts as a factor affecting inflammation, collagen turnover and sleep architecture — the same biological terrain that regenerative peptide reviews describe as relevant to repair outcomes (PMID 42635865). Connecting those two observations is an inference about biology, not a finding. No cited study measured it.

TB-500 and caffeine

Direct evidence: none identified. The verified literature contains no experiment in which caffeine and TB-500 were co-administered, and no review in the set listed caffeine among substances examined alongside regenerative peptides (PMID 42635865).

Mechanistic reasoning, not evidence: caffeine's principal routes of clearance involve hepatic cytochrome enzymes, whereas peptide clearance is more often discussed in terms of proteolysis and renal handling. Reviewers describing peptide mechanisms in aging biology framed peptide activity in receptor- and signalling-level terms rather than in terms of shared hepatic enzyme competition (PMID 42021992). On that reasoning, investigators would not predict a classical metabolic interaction — but a prediction from mechanism is not a measurement, and the verified set contains no measurement.

TB-500, food, fasting and meal timing

Direct evidence: none identified. No fed-versus-fasted crossover, no food-effect pharmacokinetic study, and no meal-timing comparison involving TB-500 appears in the verified literature. The rat study's endpoints were histopathological and biomechanical tendon measures rather than absorption parameters (PMID 42542926).

Mechanistic reasoning, not evidence: food-effect studies are standard for orally administered agents because gastric emptying, bile flow and intestinal transporters alter absorption. Peptides in the regenerative literature are most often described in injectable form, which is why reviews of clinical peptide applications discuss administration route and stability rather than meal timing (PMID 42635865). Separately, nutritional status is discussed in tissue-repair biology as an input to collagen synthesis and cellular remodelling, themes that overlap with the mechanisms described for therapeutic peptides in aging contexts (PMID 42021992). Those are parallel discussions, not a demonstrated interaction.

TB-500 with other peptides, including BPC-157

This is the one pairing with a primary study attached to it. Researchers evaluated BPC-157 and TB-500 in the same rat Achilles tendon healing investigation, assessing outcomes with both histopathological scoring and biomechanical testing (PMID 42542926). The study design is what matters for interpretation: examining two peptides within one experiment establishes comparative and combination context in a rodent tendon model, and the study reported outcomes at the tissue and mechanical level rather than in human participants (PMID 42542926).

Review-level sources place that kind of finding in perspective. The regenerative-medicine review described clinical applications of peptides in tissue repair and chronic pain management while noting the preliminary character of much of the supporting work (PMID 42635865). Extrapolating a rodent tendon result to any human combination scenario is an inference the cited papers do not make.

Other compounds readers ask about

• Anti-inflammatory drugs: no verified study co-administered an NSAID or corticosteroid with TB-500; the tendon study's arms were peptide and control groups (PMID 42542926).
• Anticoagulants: no verified study measured coagulation endpoints with TB-500 co-exposure (PMID 42635865).
• Growth-hormone-axis peptides: the gerontology review discussed peptide mechanisms relevant to aging biology but did not report a controlled TB-500 combination experiment (PMID 42021992).
• Vitamins, collagen and amino-acid supplements: not examined alongside TB-500 in any verified source (PMID 42635865).

Evidence status at a glance

Adverse Events and Combination Signals: What Studies Report

Because no verified study exposed animals or humans to TB-500 plus alcohol, caffeine or a defined dietary state, no combination-specific adverse event has been reported in this evidence set. The rat tendon investigation reported outcomes through histopathological and biomechanical assessment of healing tissue rather than through a systematic human safety register (PMID 42542926). Reviews covering peptides in regenerative medicine described clinical applications in tissue repair and chronic pain management alongside the limitations of the current evidence, which is the context in which any safety statement about these compounds should be read (PMID 42635865). The gerontology review likewise framed therapeutic peptides in mechanistic and application terms rather than presenting pooled adverse-event data for TB-500 combinations (PMID 42021992). Absence of reported events in a small preclinical literature is not the same as demonstrated absence of risk.

How an interaction question would ordinarily be answered

Pharmacology answers interaction questions with specific designs, and none of them has been applied to TB-500 in the verified record:

1. Pharmacokinetic co-administration studies measuring exposure with and without the second substance.
2. Enzyme and transporter assays identifying shared metabolic routes — a framework built for small molecules, which reviews of peptide mechanisms treat differently from classical drug metabolism (PMID 42021992).
3. Factorial animal models in which an injury model is crossed with the second exposure, unlike the peptide-versus-control structure of the rat tendon study (PMID 42542926).
4. Controlled human trials with adverse-event capture, the level of evidence that peptide reviews identify as still developing for regenerative applications (PMID 42635865).

Limitations of this summary

Three sources cannot describe an entire field. The available primary work is a rodent tendon experiment with histopathological and biomechanical endpoints (PMID 42542926), and the remaining sources are reviews of peptide applications and mechanisms rather than interaction analyses (PMID 42635865). Animal findings do not transfer directly to people, and mechanistic plausibility has repeatedly failed to predict real interactions in other drug classes. Readers comparing sources should check whether a claim about TB-500 and any other substance carries a citation to an experiment that actually tested the pairing, or whether it is reasoning presented as data.

Related reading: TB-500 overview.

References

• Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study (Joint Diseases and Related Surgery, 2026)
• Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management (Current Pain and Headache Reports, 2026)
• Therapeutic peptides in gerontology: mechanisms and applications for healthy aging (Frontiers in Aging, 2026)